Published in Medical Verdicts and Law Weekly, January 18th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Hollis-Eden Pharmaceuticals.
Report 1: Hollis-Eden Pharmaceuticals, Inc., (HEPH) provided an update on its progress in negotiations with the U.S. Department of Health & Human Services (HHS) on a potential BioShield procurement contract for Neumune, the company's lead drug candidate for Acute Radiation Syndrome (ARS).
As previously announced, Hollis-Eden was informed by HHS in late June the company "is within the competitive range for discussion and further...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly